Ben Derman, MD, specializes in hematology and oncology. Dr. Derman is an expert in multiple myeloma and other plasma cell disorders, such as monoclonal gammopathy, amyloidosis, plasmacytoma, and POEMS syndrome. He also diagnoses and treats cancerous conditions and uses the most innovative techniques, including CAR T-cell therapy and stem cell transplantation to deliver long-term success for his patients.
Along with his clinical practice, Dr. Derman remains committed to research. Currently, he is focused on identifying strategies that can lead to a possible cure for multiple myeloma, including using very sensitive tests that measure small amounts of residual cancer cells in the body called ‘minimal residual disease’ (MRD) to guide decision making.
Dr. Derman is also investigating new methods and therapies designed to improve outcomes and quality of life for his patients. Additionally, he is interested in evaluating reasons for racial disparities in multiple myeloma outcomes to better understand and care for those patients. His work has been published in several peer-reviewed journals, including the Journal of Immunotherapy of Cancer, Blood, Blood Advances, Blood Cancer Journal, Leukemia and Lymphoma and British Journal of Haematology.
Specialties
Areas of Expertise
Board Certifications
- Hematology
- Internal Medicine
Memberships & Medical Societies
- American Society of Hematology
- American Society for Blood and Marrow Transplantion
- American Society of Clinical Oncology
Practicing Since
- 2013
Languages Spoken
- English
- Spanish
Medical Education
- Northwestern University Feinberg School of Medicine
Residency
- Rush University Medical Center
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
- Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
- Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
- Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
- BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
- Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
- Study of bb21217 in Multiple Myeloma
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient